Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Alexion Pharmaceuticals

Biotech & Life Sciences · Boston, United States · Founded 1992 · IPO 1996 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$39B
Market cap · 2026
Revenue
$8.90B
Latest reported FY
EBITDA
$4.04B
Latest reported FY

World Leader in Treatments for Patients with Devastating and Rare Diseases

Investors

3 investors on Alexion Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Oak Investment Partners
CHL Medical Partners
Invesco

Global footprint

Where Alexion Pharmaceuticals has talent and traffic

AI talent share
0.7% of workforce is AI talent
(38 of 5,099 staff)
Core AI70.14%
Other AI310.61%
Non-AI workforce5,06199.25%
Workforce by country
48 countries with
team presence
🇺🇸 United States45%
🇮🇪 Ireland21.4%
🇪🇸 Spain6.4%
🇨🇦 Canada4.9%
🇫🇷 France3.6%
Top 5 of 48 shown
Web traffic by country
72K monthly visits
across markets
🇺🇸 United States29.2%
🇮🇳 India16.5%
🇨🇦 Canada10.7%
🇬🇧 United Kingdom7.2%
🇮🇪 Ireland4.6%
Top 5 markets shown

Patent intelligence

$444M patent portfolio · 245 active families

Estimated portfolio value
$444M
1.1% of market cap · 2.4× the top peer Amryt Pharma ($184M)
245 active patent families
Where Alexion Pharmaceuticals innovates DiseaseMolecular biologyAntiendomysial antibodiesAnti antibodyPharmaceutical drug

Where Alexion Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Alexion Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Alexion Pharmaceuticals's 8 investments and acquisitions.

Every disclosed deal where Alexion Pharmaceuticals appeared as a backer or acquirer, 2011–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across Alexion Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Alexion Pharmaceuticals's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        8 of 8 deals

        Sentiment on X

        What X is saying about Alexion Pharmaceuticals

        An AI-synthesized read of the highest-engagement posts about Alexion Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Alexion Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.